We’re excited to share that our FDA approval for Generic Eribulin Mesylate Injection has been featured in Pharmacy Angle! This significant milestone brings a more accessible treatment option to help in the fight against breast cancer. At Long Grove Pharmaceuticals, we’re dedicated to delivering high-quality, differentiated solutions that truly impact patient care. Read the full feature to learn more: https://lnkd.in/gJreiZAF
Long Grove Pharmaceuticals的动态
最相关的动态
-
Explore the different types of #cancer, treatment options, and the significance of early detection. Pinnacle Life Science excels in manufacturing high-quality cancer medications. Partner with us to enhance your pharmaceutical offerings and improve patient care. Contact us today to discuss collaboration opportunities. #CancerAwareness #EarlyDetectionSavesLives #TreatmentOptions #HighQualityMedications #PatientCare #PharmaceuticalOfferings #CollaborationOpportunities #CancerResearch #MedicalInnovation #PinnacleLifeScience
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Thoughts on this? >> FDA approves AstraZeneca and Daiichi Sankyo’s ADC for breast cancer despite lack of survival benefit >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #productmarketing #pharma #biotech #healthcare
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Thoughts on this? >> FDA approves endometrial cancer indications for Keytruda, Imfinzi >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #pharma #productmarketing #healthcare #pharmaceutical
FDA approves endometrial cancer indications for Keytruda, Imfinzi
https://endpts.com
-
Thoughts on this? >> FDA approves endometrial cancer indications for Keytruda, Imfinzi >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #pharmaceutical #biotech #productmarketing #healthcare
FDA approves endometrial cancer indications for Keytruda, Imfinzi
https://endpts.com
-
Thoughts on this? >> FDA approves AstraZeneca and Daiichi Sankyo’s ADC for breast cancer despite lack of survival benefit >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #productmarketing #biotech #healthcare #pharmaceutical
FDA approves AstraZeneca and Daiichi Sankyo’s ADC for breast cancer despite lack of survival benefit
endpts.com
-
Great article from FirstWord with Loxo@Lilly EVP Jacob Van Naarden on their ambitions for targeted radiopharmaceuticals: https://lnkd.in/eR9grXD6 I took away 3 key success factors for a targeted radiopharmaceutical franchise: -Assurance of radionuclide supply (either through manufacturing or supply chain relationships) and contingent upon radionuclide supply and other factors, the ability for manufacturing to meet demand -Radionuclide diversity, both to hedge against supply constraints as well as to address different therapeutic goals (also discussed here: https://lnkd.in/ecDEsU5y) -Breadth of targets / tumor types in the clinical development plan (also discussed in the article mentioned above)
ViewPoints: Eli Lilly EVP maps out growing radiotherapy ambitions
ml.firstwordpharma.com
-
BioPharma & HealthTech Competitive Strategy & Insights | Digital & AI Solutions | Gene & Cell Therapy | Vaccines
Thoughts on this? >> Bristol Myers' cancer drug Augtyro wins new accelerated approval in solid tumors >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #healthcare #pharma #pharmaceutical #productmarketing
Bristol Myers' cancer drug Augtyro wins new accelerated approval in solid tumors
endpts.com
-
Thoughts on this? >> Bristol Myers' cancer drug Augtyro wins new accelerated approval in solid tumors >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #biotech #pharmaceutical #productmarketing #healthcare
Bristol Myers' cancer drug Augtyro wins new accelerated approval in solid tumors
endpts.com
-
Thoughts on this? >> Merck and Daiichi’s rejected HER3 ADC clears a Phase 3 in certain lung cancers >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #pharma #biotech #healthcare #productmarketing
Merck and Daiichi’s rejected HER3 ADC clears a Phase 3 in certain lung cancers
endpts.com
-
Merck has said a subcutaneous version of the immunotherapy passed a Phase 3 a decade after Keytruda hit the market. Roche snagged the first FDA approval for a subcutaneous PD-L1-targeting drug in September. Kyle LaHucik reports: https://lnkd.in/e8QGvwfh
Merck finally has subcutaneous Keytruda results, and it's going to regulators
endpts.com
